Alector announces closing of public offering

South san francisco, calif., jan. 19, 2024 (globe newswire) -- alector, inc. (nasdaq: alec), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the closing of its underwritten public offering of shares of its common stock. alector sold 10,869,566 shares of its common stock in the offering. alector has granted the underwriter a 30-day option to purchase up to an additional 1,630,434 shares of its common stock. the gross proceeds to alector from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are approximately $75 million.
ALEC Ratings Summary
ALEC Quant Ranking